Here are the DEF 14A proxy statements from cbdMD, Inc. (YCBD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow YCBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YCBD filings page.
cbdMD, Inc. is asking shareholders at its March 30, 2026 virtual annual meeting to approve eight proposals, including electing seven directors and ratifying Cherry Bekaert LLP as auditor for fiscal 2026. Only common shareholders as of February 2, 2026, when 10,495,561 shares were outstanding, may vote.
The board seeks discretionary authority for a reverse stock split between 1‑for‑2 and 1‑for‑10 to help address NYSE American listing price requirements and increase flexibility for future issuances. The split would reduce outstanding shares but keep authorized shares unchanged, increasing the number available for future use.
Shareholders are also asked to approve, under NYSE American Section 713, potential issuances exceeding 20% of outstanding stock tied to Series B and Series C Convertible Preferred Stock (each with 10% annual dividends and price‑protection features) and a $20 million equity line of credit with C/M Capital Master Fund, LP. These approvals, along with a new 2025 Equity Compensation Plan and a possible meeting adjournment, could lead to significant dilution relative to current ownership if fully utilized.